Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.
Who will be affected?
Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Online patient attitudes towards cutaneous immune-related adverse events attributed to nivolumab and pembrolizumab: a sentiment analysis of drugs.com
Camille M. Powers;
Andrew K. Yang;
Hannah Verma;
Jeremy Orloff;
Austin J. Piontkowski;
Nicholas Gulati
ABSTRACT
With the advent of immune checkpoint inhibitors (ICIs) for cancer treatment, patients use online forums to share experiences. As many as 60% of patients taking ICIs will develop cutaneous immune-related adverse events, which can be a good prognostic indicator for ICI treatment response. This paper explores patient sentiments in online reviews on drugs.com to ICIs, pembrolizumab and nivolumab, using Python with Selenium and manual review. There were statistically significant higher mean overall patient ratings in reviews mentioning dermatologic symptoms (DS) compared to those that did not (mean of 5.7/10 vs. 4.0/10, P=.007), and a trend towards higher sentiment scores as well (P=.074). Finally, DS-containing reviews more frequently reported positive cancer outcomes (P<.001).
Citation
Please cite as:
Powers CM, Yang AK, Verma H, Orloff J, Piontkowski AJ, Gulati N
Online Patient Attitudes Toward Cutaneous Immune-Related Adverse Events Attributed to Nivolumab and Pembrolizumab: Sentiment Analysis